Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer

Dunne, Michael; Dou, Yannan N.; Drake, Danielle M.; Spence, Tara; Gontijo, Sávio Morato de Lacerda; Wells, Peter G.; Allen, Christine

doi:10.1016/j.jconrel.2018.04.029

Cited by 39 publications

(20 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRgFUS can achieve mild temperature elevations within the hyperthermia regime ( 26 ) as well as high-temperature ablations, both of which can be combined with thermosensitive drugs ( 27 ). Several groups have developed thermosensitive drug delivery systems that incorporate other forms of commonly used chemotherapeutic agents, such as cisplatin ( 28 ), that can be delivered with MRgFUS hyperthermia, and some have begun to evaluate multiple thermosensitive drug cocktails to maximize tumor-specific cytotoxicity ( 29 ). Therefore, by overcoming the limitations on clinical MRgFUS hyperthermia, this noninvasive treatment strategy can be used on a broader spectrum of tumor indications to both improve patient outcomes and reduce treatment-associated side effects.…”

Section: Discussionmentioning

confidence: 99%

Novel fractionated ultrashort thermal exposures with MRI-guided focused ultrasound for treating tumors with thermosensitive drugs

Santos

Regenold

et al. 2020

Sci. Adv.

Self Cite

View full text Add to dashboard Cite

Thermosensitive liposomes represent an important paradigm in oncology, where hyperthermia-mediated release coupled with thermal bioeffects enhance the effectiveness of chemotherapy. Their widespread clinical adoption hinges upon performing controlled targeted hyperthermia, and a leading candidate to achieve this is temperature-based magnetic resonance imaging (MRI)–guided focused ultrasound (MRgFUS). However, the current approach to hyperthermia involves exposures lasting tens of minutes to hours, which is not possible to achieve in many circumstances because of blood vessel cooling and respiratory motion. Here, we investigate a novel approach to overcome these limitations: to use fractionated ultrashort (~30 s) thermal exposures (~41° to 45°C) to release doxorubicin from a thermosensitive liposome. This is first demonstrated in a dorsal chamber tumor model using two-photon microscopy. Thermal exposures were then conducted with a rabbit tumor model using a custom MRgFUS system incorporating temperature feedback control. Drug release was confirmed, and longitudinal experiments demonstrated profoundly enhanced tumor growth inhibition and survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel fractionated ultrashort thermal exposures with MRI-guided focused ultrasound for treating tumors with thermosensitive drugs

Santos

Regenold

et al. 2020

Sci. Adv.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other liposomal carriers have been recently designed and investigated in vitro and in vivo . Mild hyperthermia was used to effectively trigger release of cisplatin from thermo-sensitive liposomes in the vasculature of a human model of triple-negative breast cancer (MDA-MB-231 and MDA-MB-436) resulting in a significant tumor growth delay [ 111 ]. The liposomes used in this study had a lipid phase transition temperature of 41.5 °C and demonstrated their efficiency in a previous work on mice bearing subcutaneously-implanted ME-180 cervical tumor [ 112 ].…”

Section: Biomedical Applications Of Thermal-nanomaterialsmentioning

confidence: 99%

Thermo-Sensitive Nanomaterials: Recent Advance in Synthesis and Biomedical Applications

et al. 2018

View full text Add to dashboard Cite

Progress in nanotechnology has enabled us to open many new fronts in biomedical research by exploiting the peculiar properties of materials at the nanoscale. The thermal sensitivity of certain materials is a highly valuable property because it can be exploited in many promising applications, such as thermo-sensitive drug or gene delivery systems, thermotherapy, thermal biosensors, imaging, and diagnosis. This review focuses on recent advances in thermo-sensitive nanomaterials of interest in biomedical applications. We provide an overview of the different kinds of thermoresponsive nanomaterials, discussing their potential and the physical mechanisms behind their thermal response. We thoroughly review their applications in biomedicine and finally discuss the current challenges and future perspectives of thermal therapies.

show abstract

“…1 Despite the modern therapeutic strategies that have been developed, conventional chemotherapy remains a crucial significance, including the drugs of paclitaxel (PTX), cisplatin, doxorubicin, and so on. [2][3][4] PTX is an effective drug chemotherapy in clinical treatment for BC, and the combined therapy based on PTX is usually as first-line therapy. [5][6][7] However, the acquired resistance might seriously affect the therapeutic effect to cause the eventual failure of treatment.…”

Section: Introductionmentioning

confidence: 99%

<p>Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis</p>

Liu¹,

Jiang²,

Zhang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Paclitaxel (PTX) occupies a considerable status in the chemotherapies of breast cancer (BC), but the drug resistance keeps an obstructive factor of PTX treatment. This study was designed to explore the molecular mechanism of long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) in PTX resistance of BC. Methods: UCA1, microRNA-613 (miR-613) and cyclin-dependent kinase 12 (CDK12) expression was assayed through quantitative real-time polymerase chain reaction (qRT-PCR). Cell Counting Kit-8 (CCK-8) assay was implemented for evaluating the half inhibitory concentrations (IC 50) of PTX and cell viability. Cell apoptosis was examined by flow cytometry. The target relationship was explored using dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. CDK12 protein level was detected through Western blot. Xenograft tumor assay was applied for assessing the influence of UCA1 on PTX resistance of BC in vivo. Results: UCA1 expressed highly in PTX-resistant BC tissues and cells and regulated PTX resistance in BC cells by affecting cell viability and apoptosis in part. UCA1 negatively interacted with miR-613 and modulated PTX resistance via sponging miR-613. CDK12 was a downstream gene of miR-613 and miR-613 exerted the modulation of PTX resistance via targeting CDK12. Furthermore, UCA1 regulated CDK12 level through interacting with miR-613. The regulatory role of UCA1 in PTX resistance of BC was achieved by miR-613/ CDK12 axis in vivo. Conclusion: UCA1 mediated PTX resistance in BC through the miR-613/CDK12 axis, manifesting that UCA1 might improve the PTX treatment of BC as a significant therapeutic biomarker.

show abstract

Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer

Cited by 39 publications

References 56 publications

Novel fractionated ultrashort thermal exposures with MRI-guided focused ultrasound for treating tumors with thermosensitive drugs

Novel fractionated ultrashort thermal exposures with MRI-guided focused ultrasound for treating tumors with thermosensitive drugs

Thermo-Sensitive Nanomaterials: Recent Advance in Synthesis and Biomedical Applications

<p>Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis</p>

Contact Info

Product

Resources

About